Antipsychotic Treatment in Breast Cancer Patients

Rahman, Tahir; Clevenger, Charles V.; Kaklamani, Virginia; Campbell, Austin; Malwitz, Kari; Kirkland, Robert S.

doi:10.1176/appi.ajp.2013.13050650

Cited by 32 publications

(48 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, it has been shown in vitro that (prolactin‐elevating) phenothiazines may enhance the effect of tamoxifen, a first‐line adjuvant treatment for breast cancer patients, in human breast cancer cells . Thus, to date, no robust evidence exists for an increased risk of breast cancer due to antipsychotic‐induced hyperprolactinemia .…”

Section: Neoplasmsmentioning

confidence: 99%

Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder

et al. 2015

View full text Add to dashboard Cite

People with severe mental illness have a considerably shorter lifespan than the general population. This excess mortality is mainly due to physical illness. Next to mental illness-related factors, unhealthy lifestyle, and disparities in health care access and utilization, psychotropic medications can contribute to the risk of physical morbidity and mortality. We systematically reviewed the effects of antipsychotics, antidepressants and mood stabilizers on physical health outcomes in people with schizophrenia, depression and bipolar disorder. Updating and expanding our prior systematic review published in this journal, we searched MEDLINE (November 2009 -November 2014, combining the MeSH terms of major physical disease categories (and/or relevant diseases within these categories) with schizophrenia, major depressive disorder and bipolar disorder, and the three major psychotropic classes which received regulatory approval for these disorders, i.e., antipsychotics, antidepressants and mood stabilizers. We gave precedence to results from (systematic) reviews and meta-analyses wherever possible. Antipsychotics, and to a more restricted degree antidepressants and mood stabilizers, are associated with an increased risk for several physical diseases, including obesity, dyslipidemia, diabetes mellitus, thyroid disorders, hyponatremia; cardiovascular, respiratory tract, gastrointestinal, haematological, musculoskeletal and renal diseases, as well as movement and seizure disorders. Higher dosages, polypharmacy, and treatment of vulnerable (e.g., old or young) individuals are associated with greater absolute (elderly) and relative (youth) risk for most of these physical diseases. To what degree medication-specific and patient-specific risk factors interact, and how adverse outcomes can be minimized, allowing patients to derive maximum benefits from these medications, requires adequate clinical attention and further research.

show abstract

Section: Neoplasmsmentioning

confidence: 99%

Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It was considered that because patients with breast cancer had prolactin receptor overexpression, antipsychotics could trigger the activation of prolactin receptor, leading to tumorgenesis and proliferation of cancer cells in some patients (118). According to a case-controlled study conducted on the basis of the hypothesis that breast cancer could develop due to the use of antidepressants, it was found that SSRI and other antidepressants did not increase the risk of breast cancer; nevertheless, such risk might scale up due to use of tricyclic antidepressants for more than 2 years (119). A similar study concluded that exposure to tricyclic antidepressants at higher doses for more than 10 years would partly escalate the risk of getting breast cancer (120).…”

Section: Impacts Of Psychopharmacologic Drugs On Breast Cancermentioning

confidence: 99%

Psychiatric Symptoms and Psychosocial Problems in Patients with Breast Cancer

et al. 2016

View full text Add to dashboard Cite

“…The aetiology of breast cancer is complicated with many contributing aspects, including a number of endocrine factors [2]. Prolactin, a hormone essential to growth and differentiation of mammary gland cells [3][4][5][6][7], is likely to play a role in the aetiology of breast cancer, although this is somewhat controversial and incompletely understood [3,[7][8][9][10]. Upon binding of the ligand, the prolactin receptor initiates various downstream pathways that improve differentiation, proliferation and survival of epithelial cells of mammary glands [11,12].…”

Section: Introductionmentioning

confidence: 99%